AlphAIalphai — Financial news for AI agents
manilatimes.netJUN 124 min read$IVA

Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing

Inventiva said it completed June 12, 2026 steps of its EIB and new debt financing. According to the company, it repaid EIB loans in full for about €62.2m and repurchased/cancelled EIB warrants for €50m (including 700,000 Tranche B warrants). It also issued Tranche A €35m convertible bonds and Tranche B €40m amortized bonds for initial gross proceeds €75m, with net proceeds €71.3m.

Original reporting
manilatimes.net
Published Jun 12, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 9:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing — source image
Source · manilatimes.net
Decision brief

The 30-second read

$IVANeutralMed
01

Why it matters

The company ties the EIB repayment and debt issuance to the equity offering closing, and now confirms the transaction steps are completed with specified conversion and exercise prices.

02

Market read

This is a capital-structure event: secured debt replaces EIB exposure and provides net proceeds, while convertible/warrant terms define future dilution risk.

03

What to watch

Remaining EIB warrants require shareholder approval for cancellation; timing of the June 30, 2026 general meeting could create event-driven volatility.

Relevance 8/10Novelty 8/10Timing: after-hours / same-day (June 12, 2026) completion of financing steps

Background

Inventiva previously announced a combined transaction (EIB loan repayment/warrant repurchase plus new debt tranches) contingent on completing an equity financing.

Company-level read

Ticker impact

$IVANeutralMedium confidence
Context

Inventiva completed €62.2m EIB loan repayment, repurchased EIB warrants for €50m, and issued €75m new debt tranches with €71.3m net proceeds.

Expected impact

Likely near-term support from funding clarity, offset by dilution/warrant overhang; watch for sensitivity to conversion/exercise pricing versus recent equity levels.

Evidence & confidence

The article discloses concrete financing mechanics (repayment, tranche sizes, conversion price €5.2893, warrant exercise price €4.1559) that directly affect capital structure and dilution risk.

Market effects

Sector

Biopharma clinical-stage issuers may see read-across for EIB-style secured financing structures and the market’s tolerance for dilution tied to conversion/warrants.

Regional

Supports sentiment for European small/mid-cap biopharma names with US listings when they close cross-border financing.

Global

Limited beyond the issuer; however, it signals continued availability of structured debt financing for cash-burn biotech.

Counterpoint

What could challenge this read

The net proceeds are meaningful, but the conversion ratio and warrant exercise price imply future share issuance risk that can cap upside even after funding clarity.

Key entities

  • company
    Inventiva

    Clinical-stage biopharma developing oral therapy for MASH (lanifibranor).

  • lender
    EIB

    European Investment Bank; loans repaid and warrants repurchased/cancelled as part of the restructuring.

  • lenders
    BlackRock and Claret Capital Partners

    Funds/accounts managing the lenders under the subscription agreement for the new debt tranches.

Read at source← All news

Related articles

JUL 30
$IVAMed

INVENTIVA: Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026

Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 30, 2026 - Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026. On page 2, the potential proceeds for the Tranche C of the Debt Financing Transaction was mistakenly stated as €20 million. The correct figure is €55 million.

finanznachrichten.de4 min
JUL 29
$IVAMed

INVENTIVA: Inventiva Announces Preliminary Financial Results for the First Half of 2026

Inventiva (Euronext Paris and Nasdaq: IVA) reported preliminary 1H 2026 results. Cash and cash equivalents were €166.1 million at June 30, 2026, versus €99.3 million at Dec. 31, 2025. Net cash used in operating activities was (€48.7) million. R&D expenses were (€50.1) million. No revenues were recorded. The company expects funding into Q2 2027, or Q1 2028 with potential tranches.

finanznachrichten.de4 min
JUN 23
$IVAMedAI 8/10

Gide advises Inventiva on a comprehensive capital structure optimization including debt and equity financing Gide

Gide advised Inventiva, a biopharmaceutical company, on combined cross-border financing. According to Gide, Inventiva raised about $120m via an offering of American depositary shares in the U.S., and arranged new bond and convertible bond financing of €75m initially (up to €130m subject to conditions). The transactions also included a €50m repurchase of EIB warrants and full repayment of existing EIB debt. Cooley advised on U.S. law.

gide.com2 min
JUN 12
$IVAMedAI 8/10

INVENTIVA: Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing

Inventiva said it completed key steps of a combined EIB and new debt financing transaction on June 12, 2026. It prepaid EIB loans of about €62.2m and repurchased/cancelled EIB warrants for €50m (including 700,000 Tranche B warrants). It issued Tranche A convertible bonds (€35m) and Tranche B amortized bonds (€40m) for €71.3m net proceeds, with conversion price €5.2893 and lender warrant exercise price €4.1559.

finanznachrichten.de4 min